MichaelaLTsaiMD

Oncology • Seattle, WA

Medical Director of Breast Oncology Deputy Director of Clinical Operations

Join to view full profile

Dr. Tsai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tsai's full profile

Already have an account?

Office
1221 Madison St
Suite 500
Seattle, WA 98104
Phone+1 206-386-2828

Fax+1 206-386-3782
Is this information wrong?

Summary

Dr. Michaela Tsai is a medical oncologist and hematologist. She is the medical director of the breast oncology program at the Swedish Cancer Institute in Seattle, WA. She also directs the breast clinical research program, the survivorship program, and the cancer genetics program.

Education & Training

Harvard Medical SchoolClass of 1998
Duke UniversityBS, Chemistry and Religion, Summa Cum Laude, 1990 - 1994

Certifications & Licensure

WA State Medical License 2021 - 2025
AK State Medical License 2023 - 2024
MN State Medical License 2000 - 2021
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020.
Ed Y Kim, Daniela Duarte-Bateman, Bonny Chau, Michael J Wagner, Vinod Ravi, Stephanie K Schaub, Jeremy Sharib, Harveshp Mogal, Min Park, Michaela Tsai, Anthony Tufaro,...> ;JAMA Network Open. 2024 Apr 1
1 citations
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Catherine S Diefenbach, Thomas A Jandl, William Novotny, Jane Huang, Lu Miao, Prabhu Rajagopalan, Richard G Ghalie, Jacob D Soumerai, Deepa Jagadeesh, Adam Asch, Abhij...> ;British Journal of Haematology. 2024 Mar 19
69 citations
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Edward S Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M Shagan, Sylvia Hu, Young Kwang Chae, Ticiana A Leal, Jonathan E Dowell, Michaela L Tsai, Christophe...> ;Nature Medicine. 2022 May 1
104 citations
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika...> ;Annals of Oncology. 2021 Sep 1
2 citations
HER2 Testing: Insights From Pathologists' Perspective on Technically Challenging HER2 FISH Cases
Erin V Grimm, Kimberly H. Allison, David G. Hicks, Karen K. Swenson, Janet Krueger, Hadi Yaziji, Erinn Downs-Kelly, Mara Hester Rendi, Barbara Susnik, Michaela L. Tsai...> ;Applied Immunohistochemistry & Molecular Morphology. 2021 Jul 19
64 citations
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, D. R. D'Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O'Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou...> ;Clinical Cancer Research. 2021 Jun 1
1 citations
HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tamera J. Lillemoe, Mara Hester Rendi, Michaela L. Tsai, Monica Knaack, Rina Yarosh, Erin Grimm, Barbara Susnik, Janet Krueger, Susan Olet, Karen K. Swenson> ;International Journal of Breast Cancer. 2021 May 24
34 citations
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller, Prapti A. Patel, Alexander I. Spira, Michaela L. Tsai, Errin Samuelsz, Sandra Silberman...> ;Clinical Cancer Research. 2020 Sep 30
1 citations
Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
Michaela L. Tsai, Monica Knaack, Parker Martone, Janet Krueger, Shari Baldinger, Tamera J. Lillemoe, Barbara Susnik, Erin Grimm, Susan Olet, Natasha Rueth, Karen K. Sw...> ;Clinical Breast Cancer. 2021 Feb 1
11 citations
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.
Lee S Schwartzberg, Hidehito Horinouchi, David Chan, Sara Chernilo, Michaela L Tsai, Dolores Isla, Carles Escriu, John P Bennett, Kim Clark-Langone, Christer Svedman, ...> ;NPJ Precision Oncology. 2020 Jan 1
10 citations
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab, Donald A. Richards, Joseph A. Sparano, J. Thad Beck, Paul Richards, Patrick J. Ward, Bhuvaneswar...> ;Clinical Breast Cancer. 2019 Feb 28
6 citations
Predictive value of breast magnetic resonance imaging in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contral...
Barbara Susnik, Lisa Schneider, Karen K. Swenson, Janet Krueger, Christina Braatz, Tamera J. Lillemoe, Michaela Tsai, Todd E. DeFor, Monica Knaack, Natasha Rueth> ;Journal of Surgical Oncology. 2018 Jul 1
67 citations
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
Ryan J. Hartmaier, Sally E. Trabucco, Nolan Priedigkeit, Jon Chung, Christine A. Parachoniak, P. Vanden Borre, Samantha Morley, Margaret Rosenzweig, Michael E. Goldber...> ;Annals of Oncology. 2018 Apr 1
12 citations
Clinicopathologic analysis of a large series of microinvasive breast cancers
Tamera J. Lillemoe, Michaela L. Tsai, Karen K. Swenson, Barbara Susnik, Janet Krueger, Kendra Harris, Natasha Rueth, Erin Grimm, Joseph W. Leach> ;The Breast Journal. 2018 Feb 24
34 citations
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Wolfgang Janni, Emilio Alba, Thomas Bachelot, Sami Diab, Miguel Gil-Gil, Thaddeus Beck, Larisa Ryvo, Rafael López, Michaela Tsai, Francisco J. Esteva, Pilar Zamora Auñ...> ;Breast Cancer Research and Treatment. 2018 Feb 5
32 citations
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gen...
Michaela Tsai, Shelly S. Lo, William Audeh, Rubina Qamar, Raye Budway, Ellis G. Levine, Pat Whitworth, B Mavromatis, Robin Zon, Dwight Oldham, Sarah Untch, Tina Treece...> ;JAMA Oncology. 2018 Jan 11
48 citations
Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)
Debra L. Barton, Jeff A. Sloan, Lynne T. Shuster, Paula Gill, Patricia C. Griffin, Kathleen A. Flynn, Shelby A. Terstriep, Fauzia N. Rana, Travis J. Dockter, Pamela J....> ;Supportive Care in Cancer. 2018 Feb 1
4 citations
Pathologic Predictors of Treatment Response to Neo-adjuvant Chemotherapy for Invasive Lobular Breast Carcinoma.
Michaela Tsai, Marsha Finkelstein, Tamera J. Lillemoe, Barbara Susnik, Erin Grimm, Sung-Hae Kang, Caitlin Kelly, Karen K. Swenson> ;The Breast Journal. 2017 Mar 22
28 citations
Surgical Outcomes of Lobular Neoplasia Diagnosed in Core Biopsy: Prospective Study of 316 Cases.
Barbara Susnik, Deborah Day, Ellen Abeln, Tara Bowman, Janet Krueger, Karen K. Swenson, Michaela L. Tsai, Margit L. Bretzke, Tamera J. Lillemoe> ;Clinical Breast Cancer. 2016 Dec 1
37 citations
Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
Alyssa Kne, Heather Zierhut, Shari Baldinger, Karen K. Swenson, Pamela J. Mink, Patricia McCarthy Veach, Michaela L. Tsai> ;Journal of Genetic Counseling. 2017 Aug 1
38 citations
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmun...
Andre Goy, Andres Forero, Nina D. Wagner-Johnston, W. Christopher Ehmann, Michaela Tsai, Kiyohiko Hatake, Revathi Ananthakrishnan, Angela Volkert, Erik Vandendries, Mi...> ;British Journal of Haematology. 2016 Aug 1
20 citations
Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphos...
Vivek Thumbigere-Math, Bryan S. Michalowicz, Pamela J. Hughes, David L. Basi, Michaela L. Tsai, Karen K. Swenson, Laura Rockwell, Rajaram Gopalakrishnan> ;Journal of Oral and Maxillofacial Surgery. 2016 Apr 1
35 citations
Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Michaela L. Tsai, Tamera J. Lillemoe, Marsha Finkelstein, Joel E. Money, Barbara Susnik, Erin Grimm, Sung-Hae L. Kang, Karen K. Swenson> ;Clinical Breast Cancer. 2016 Feb 1
17 citations
Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw.
Vivek Thumbigere-Math, Bryan S. Michalowicz, E. P. de Jong, Timothy J. Griffin, David L. Basi, Pamela J. Hughes, Michaela L. Tsai, Karen K. Swenson, Laura Rockwell, Ra...> ;Oral Diseases. 2015 Jan 1
11 citations
Cancer rehabilitation: outcome evaluation of a strengthening and conditioning program.
Karen K. Swenson, Mary Jo Nissen, Kathryn Knippenberg, Annemiek Sistermans, Paul Spilde, Elaine M. Bell, Julia Nissen, Cathleen Chen, Michaela L. Tsai> ;Cancer Nursing. 2014 May 1
Join now to see all

Abstracts/Posters

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Michaela L. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

70-Gene Signature Impacts Treatment Decisions in Breast CAOctober 29th, 2017
New Data Shows Agendia’s MammaPrint® Can Prevent Under and over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence ScoreJune 7th, 2016
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to Their Medical Advisory BoardJune 1st, 2016
Join now to see all

Hospital Affiliations

Abbott Northwestern HospitalMinneapolis, Minnesota